InvestorsHub Logo
Followers 30
Posts 1939
Boards Moderated 0
Alias Born 01/11/2011

Re: dr_lowenstein post# 134865

Tuesday, 11/18/2014 12:48:26 PM

Tuesday, November 18, 2014 12:48:26 PM

Post# of 403281
It has happened apparently.
I'm not counting on it though in Elite's case.
But n2ka was certainly accurate.


http://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html

While the approval was not a surprise, its timing was. The F.D.A. approved the drug after only a three-month review, three months ahead of the deadline in late November. This is fairly rare, although a number of other cancer drugs have been approved at least a month ahead of deadline in recent years.

http://www.natap.org/2013/HCV/022213_01.htm

Kalydeco, the first available drug that targets the defective protein responsible for cystic fibrosis, was approved last year after a lightning-quick three-month review for the 4% of people with cystic fibrosis who harbor a particular mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene known as G551D...

This was pretty easy to find info. Not sure why it couldn't be found by others....oh wait....

"This is our year!"

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News